• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Seizures - Pipeline Review, H2 2012 Product Image

Seizures - Pipeline Review, H2 2012

  • ID: 2366405
  • December 2012
  • 59 pages
  • Global Markets Direct

Seizures – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Seizures - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Seizures, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seizures. Seizures - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Seizures.
- A review of the Seizures products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Seizures Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Seizures 8
Seizures Therapeutics under Development by Companies 10
Seizures Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Seizures Therapeutics – Products under Development by Companies 16
Seizures Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Seizures Therapeutics Development 18
UCB Group 18
Ligand Pharmaceuticals Incorporated 19
Biovitrum AB 20
Upsher-Smith Laboratories, Inc. 21
Sihuan Pharmaceutical Holdings Group Ltd. 22
Neurelis, Inc. 23
Seizures – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
lacosamide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
midazolam - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
levetiracetam - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
topiramate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
diazepam - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
buspirone hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
levetiracetam - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
bumetanide - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
levetiracetam - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
verapamil - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Seizures Therapeutics – Drug Profile Updates 45
Seizures Therapeutics – Discontinued Products 50
Seizures Therapeutics - Dormant Products 51
Seizures – Product Development Milestones 52
Featured News & Press Releases 52
Sep 24, 2012: UCB Sponsors Data Presentations On Epilepsy, Including New Data On Keppra At 10th European Congress On Epileptology 52
Sep 24, 2012: UCB Sponsors Data Presentations On Epilepsy, Including New Data On Keppra At 10th European Congress On Epileptology 52
Jul 11, 2012: Swissmedic Approves Eisai's Inovelon Oral Suspension Formulation For Seizures Associated With Lennox-Gastaut Syndrome In Switzerland 53
May 07, 2012: Abbott Reaches Settlement Agreement On Depakote 54
Apr 26, 2012: Upsher-Smith Provides Update On Phase III Seizure Clusters Study 54
Jan 09, 2012: UCB Announces Positive Top-Line Results From Phase II Open-Label Pilot Study Of Vimpat In Primary Generalized Tonic-Clonic Seizures 55
Apr 14, 2011: Ortho-McNeil Neurologics Voluntarily Recalls Two Lots Of Topamax 56
Sep 03, 2010: Stolen Shire medicines found in expired returns. 56
Apr 06, 2006: Carbatrol - Paragraph IV Notice Letter From Corepharma LLC. 57
Jul 18, 2005: Shire Pharmaceuticals Group PLC - Carbatrol Paragraph IV Litigation Update. 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Seizures, H2 2012 8
Products under Development for Seizures – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
UCB Group, H2 2012 18
Ligand Pharmaceuticals Incorporated, H2 2012 19
Biovitrum AB, H2 2012 20
Upsher-Smith Laboratories, Inc., H2 2012 21
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 22
Neurelis, Inc., H2 2012 23
Assessment by Monotherapy Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Seizures Therapeutics – Drug Profile Updates 45
Seizures Therapeutics – Discontinued Products 50
Seizures Therapeutics – Dormant Products 51

List of Figures
Number of Products under Development for Seizures, H2 2012 8
Products under Development for Seizures – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos